ALBUQUERQUE, N.M., Dec. 12 /PRNewswire/ -- Protalex Inc. (OTC Bulletin Board: PRTX), a biopharmaceutical firm announces the completion of an approximate $500,000 private placement of its common stock. The Company also continues to make substantial progress in its efforts to develop its unique approach to the management of arthritis. Almost all therapeutic approaches focus on the end product manifestations of the disease process which, by their very nature, can only alleviate symptoms. Protalex's BioRegulators modulate the disease process itself. This approach allows the biological system to re-establish its inherent control mechanisms in the complete absence of the toxic side-effects so often associated with palliation. The Company's approach involves the integration of three stages of laboratory investigation along with the immediate development of clinical application. The stages are: -- The first is an in vitro cell culture system, which allows the screening of large numbers of compounds for BioRegulator activity. BioRegulators must initiate or modulate cellular differentiation of normal cells and re-regulate the same mechanisms in abnormal cells in both animal and human models in order to qualify for further studies. -- The second system is in vivo animal models where the BioRegulator must demonstrate similar process modifying activity at dosage levels, defined by the cell culture models, which are below any known toxic levels. -- The third system is also an in vivo model. These animals have either genetic, or chemically induced arthritis-like, disease. Again, the BioRegulator must affect the animals' entire physiology in an integrated fashion. The dosage levels must be similar to those defined by both the in vitro cell culture system and the in vivo animal models. The Company can now announce the successful completion of the identification of a family of BioRegulators which meet all the Company's criteria. This family of compounds ranges from a natural product to its active, small molecular weight, subcomponents. Statements in this press release that are not strictly historical are "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements involve a high degree of risk and uncertainty, are predictions only and actual events or results may differ materially from those projected in such forward-looking statements. Factors that could cause or contribute to differences include the Company's limited operating history, uncertainty regarding viability and market acceptance of the Company's products, and the Company's dependence on reimbursement by third parties. These factors and others are more fully described in the section entitled "Risks Related to the Company's Business" in the Company's Registration Statement on Form 10-SB (File No. 000-28385) as filed with the Securities and Exchanges Commission. http://www.protalex.com
SOURCE Protalex Inc.